Cesca Therapeutics Inc. Names Mr. Mark Bagnall to the Board of Directors, Effective July 1, 2016
June 20, 2016 at 11:05 am
Share
Cesca Therapeutics Inc. announced that Mr. Mark Bagnall has been appointed to the company’s board of directors, effective July 1, 2016. Mr. Bagnall has more than 20 years of experience in senior management positions in both public and private biotechnology companies. Mr. Bagnall is the Co-Founder of Naia Pharmaceuticals where he currently serves as Director, Chief Financial Officer and Chief Operating Officer. He serves as Chairman of the Board of XCR Diagnostics and as a director on the Board of Directors of Ativa Medical. Prior to founding Naia, Mr. Bagnall served as President, Chief Executive Officer and a member of the Board of Directors of GenturaDx, until its successful sale to Luminex Corporation in 2012. He has also served as the Executive Vice president and member of the Board of Directors of ADVENTRX Pharmaceuticals.
ThermoGenesis Holdings, Inc. develops and commercializes a range of automated technologies for cell-banking, cell-processing, and cell-based therapeutics. The Company provides the AutoXpress and BioArchive platforms for automated clinical bio-banking, the PXP platform for point-of-care cell-based therapies and X-Series products for cell processing services. Its product lines include Clinical Bio-Banking Applications, Point-of-Care Applications and Cell Processing. Its Clinical Bio-Banking Applications include AXP II Automated Cell Separation System and BioArchive Automated Cryopreservation System. Its Point-of-Care Applications include PXP Point-of-Care System, and PXP-1000 System. Its Cell Processing includes X-Series Products for general laboratory use: X-Lab for cell isolation, X-Wash System for cell washing and reformulation, and X-Mini for high efficiency small scale cell purification. The Company markets and sells its medical device products through independent distributors.
THERMOGENESIS HOLDINGS, INC. 
